Stem Cell Therapy Cost-Effectiveness Parameters for Ischemic Stroke in Japan

Japanese hospital data underpins a cost-utility analysis of mesenchymal stem cell therapy for acute and subacute ischemic stroke. The dataset contains parameters for a Markov model simulation with a 10-year time horizon, created by Soichiro Takamiya and last updated in May 2026. It provides threshold costs for therapy to be considered cost-effective from different payer perspectives.

Use Cases

• Reproducing the base-case cost-effectiveness analysis based on the described Markov model parameters.
• Conducting scenario and sensitivity analyses on stem cell therapy pricing using the provided input values.
• Informing rational pricing strategies for regenerative medicine based on the calculated threshold costs.
• Comparing the cost-utility of stem cell therapy against the standard of care for stroke.

Strengths

• Specific cost-effectiveness threshold values are provided: $3,746 and $5,157 per quality-adjusted life year.
• Data is derived from a published meta-analysis on clinical efficacy.
• The model uses a defined 10-year time horizon and is based on Japanese healthcare contexts.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (13.5 KB), indicating limited scope and likely a parameter table rather than patient-level data.

Provenance

Source

figshare

Collection Method

Parameters derived from a meta-analysis and used in a Markov model simulation.

Time Range

Time horizon of the model is 10 years.

Freshness

Last updated 2026-05-21 17:26:07; freshness should be verified.

Geography

Japan (hospitals in Japan)